Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly 4Q08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Lilly 4Q08

Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve sales collectively grew 10% to $1.9 billion and accounted for 37% of total sales, compared with 33% in 4Q07.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly

4Q Revenues: $5.2 billion (flat)

4Q Loss: $3.6 billion (earnings were $854.4 million in 4Q07)

FY Revenues: $20.4 billion (+9%)

FY Loss: $2.0 billion (earnings were $3.0 billion FY08)

Comments: Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve sales collectively grew 10% to $1.9 billion and accounted for 37% of total sales, compared with 33% in 4Q07. Cymbalta sales were $721.2 million (+15%). Humalog sales were $457.9 million (+11%). Alimta sales were $318.7 million (+31%). Cialis sales for the quarter were $368.8 million (+7%). Zyprexa sales were down 10% to $1.1 billion. In 4Q08, the company completed the acquisition of ImClone Systems for approximately $6.5 billion and recorded pre-tax charges of $4.7 billion for in-process R&D. The company also recognized a charge of $80.0 million for asset impairments, restructuring and other special charges.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters